Pacritinib FDA approval date

The FDA approved Pacritinib (VONJO) on 28 Feb 2022.

FDA approval date
28 Feb 2022

Drug identity checked against registry records

Also recorded as VONJO

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806KPTIPhase 2Recruiting2027-06Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-02-28DayPacritinibFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA208712", "applicant_as_listed_by_fda": "SOBI", "brand_names": ["VONJO"], "active_ingredients": ["PACRITINIB CITRATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026